May 28, 2024

NS Pharma Shares Update on VILTEPSO® (Viltolarsen) Phase 3 Study

NS Pharma, Inc. has shared preliminary analysis results from RACER53, the global Phase 3 clinical trial of NS-065/NCNP-01 (viltolarsen). Viltolarsen is an antisense oligonucleotide drug intended to treat patients with Duchenne who are amenable to…

Learn More

November 25, 2020

Antisense Therapeutics: Introduction to the Duchenne Community

PPMD is thrilled to welcome Antisense Therapeutics to the Duchenne community. Antisense is developing a new potential therapy, ATL1102, using an antisense oligonucleotide (ASO) inhibitor aimed at treating muscle inflammation and associated muscle wasting. Although…

Learn More

October 26, 2020

Antisense Therapeutics Receives US FDA Orphan Drug Designation for ATL1102 for the Treatment of Duchenne

Antisense Therapeutics announced today that the US Food and Drug Administration (FDA) has granted an Orphan Drug Designation to the ATL1102 for treatment of Duchenne muscular dystrophy. ATL1102 is an antisense drug aimed at reducing…

Learn More

June 19, 2020

WATCH: Antisense Therapeutics Phase II Trial Final Data Results – Webinar Recording

Antisense Therapeutics recently announced that their Phase II clinical trial of ANP’s immunomodulatory therapy, ATL1102 for Duchenne in non-ambulatory patients has met its primary endpoint, confirming the safety and tolerability of ATL1102 for advancement into…

Learn More

September 25, 2019

Antisense Therapeutics Announces Positive Preliminary Results from ATL1102 for Duchenne Phase II Trial

Antisense Therapeutics has announced that a review of the preliminary data from the 6 patients who have completed their 24 weeks of dosing in the Phase II clinical trial of the company’s immunomodulatory therapy, ATL1102…

Learn More